Stock 301230 PHARMARESOURCES (SHANGHAI) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings PharmaResources (Shanghai) Co., Ltd.

Equities

301230

CNE1000065Q9

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 07/06/2024 am IST 		5-day change 1st Jan Change
29.93 CNY +1.22% Intraday chart for PharmaResources (Shanghai) Co., Ltd. -8.94% -16.40%
25/04 PharmaResources Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24/04 PharmaResources Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PHARMARESOURCES (SHANGHAI) CO., LTD. Stock PharmaResources (Shanghai) Co., Ltd.
-16.40% 442M -
MODERNA, INC. Stock Moderna, Inc.
+51.85% 57.87B
B-
LONZA GROUP AG Stock Lonza Group AG
+41.42% 40.25B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.25% 39.94B
B
CELLTRION, INC. Stock Celltrion, Inc.
-5.16% 28.54B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.79% 26.4B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.18% 19.33B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.88% 12.4B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.61% 12.23B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.06% 12.2B
B+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 301230 Stock
  4. Ratings PharmaResources (Shanghai) Co., Ltd.